LGVN News and Press, Longeveron Inc. From 08/14/22

Longeveron Inc. (LGVN) Q2 2022 Earnings Conference Call August 12, 2022 08:30 AM ET Company Participants Elsie Yau - Stern Investor Relations Chris Min - Interim Chief Executive Officer & Chief Medical Officer James Clavijo - Chief Financial Officer Joshu...

Longeveron press release ( NASDAQ: LGVN ): Q2 GAAP EPS of -$0.27. Revenue of $0.5M (+2.0% Y/Y). Cash and short-term investments was $27.0M and $35.0M as of June 30, 2022, and December 31, 2021, respectively. "We believe, based on the current operating plan and fina...

—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 202...

MIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second q...

Longeveron ( NASDAQ: LGVN ) stock gained as much as 19.9% to $7.3 in Thursday trading, after the biotech said an abstract on its phase 2a trial for its Alzheimer's Disease (AD) cell-based therapy Lomecel-B was accepted for a poster presentation at a leading AD confere...

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...

MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer ...

Longeveron Inc. (LGVN) Q1 2022 Earnings Conference Call May 13, 2022, 08:30 AM ET Company Participants Elsie Yau - Stern Investor Relations, IR Geoff Green - CEO Chris Min - Chief Medical Officer James Clavijo - CFO Joshua Hare - Chief Science Officer Conference Call Participants Michael Okun...

Longeveron press release (NASDAQ:LGVN): Q1 GAAP EPS of -$0.17 beats by $0.06. Revenue of $0.37M (-2.6% Y/Y) beats by $0.12M. We believe, based on the current operating plan and financial resources, that our existing cash and short-term investments of $30.6M will be sufficient to cover expense...

Longeveron (NASDAQ:LGVN) said Monday CEO Geoff Green will resign effective Jun. 1 to pursue new opportunities. LGVN appointed current chief medical officer K. Chris Min as interim CEO to succeed Green. The board retained an executive search firm to select a permanent CEO. LGVN intends to ente...